Abstract: Disclosed is a pharmaceutical composition containing p-aminobenzoic acid-N-D-xyloside or a pharmaceutically a acceptable salt thereof as an active ingredient.

Abstract: Disclosed herein are the derivatives of substituted cephalosporanic acid represented by the formula (I): ##STR1## wherein R.sup.1 represents a 4-pyridylthiomethyl group, an alpha-aminobenzyl group, a cyanomethyl group or a 1-tetrazolylmethyl group; R.sup.2 represents a hydrogen atom, an acetoxy group or a (5-methyl-1,3,4-thiadiazol-2-yl)thio group; R.sup.3 represents a hydrogen atom, a hydroxyl group, a carbamoyl group, an alkyl group having 1 to 4 carbon atoms or --(CONH).sub.m (CH.sub.2).sub.n --COOH wherein m is 0 or 1, n is 0, 1 or 2 and the carboxyl group may have been converted to a salt or an ester thereof; p is 0, 1 or 2 and X represents carbon atom or nitrogen atom, and antibiotics comprising the derivatives of substituted cephalosporanic acid represented by the formula (I).

Abstract: Disclosed is a pharmaceutical composition containing p-aminobenzoic acid-N-D-xyloside or a pharmaceutically a acceptable salt thereof as an active ingredient.

Abstract: Disclosed is a method for the treatment of hyperglycemia, hyperlipemia, inflammatory diseases, pains due to the accentuation of central nerve, pyrexia due to the accentuation of central nerve or tumor, which comprises administering to a patient suffering therefrom a pharmaceutically effective amount of p-aminobenzoic acid-N-L-rhamnoside or a pharmaceutically acceptable salt thereof.

Abstract: Disclosed herein are an anti-tumor substance obtained by bonding an anti-tumor agent to human immunoglobulin, and a process for producing the same.

Abstract: Disclosed herein are a cephalosporin derivative represented by the formula (I): ##STR1## wherein R.sup.1 represents a halogenoalkyl group, a salt and ester thereof, a process for producing the same, and a pharmaceutical composition and an antibacterial agent comprising the same.

Abstract: Disclosed is a pharmaceutical composition containing an aminobenzoic acid derivative as an active ingredient represented by the following general formula: ##STR1## wherein .sup.1 R denotes one member selected from the group consisting of the residual groups formed by removing OH at 1(alpha) or 1(beta) position from arabinose, xylose, glucose, galactose, rhamnose and mannose, and .sup.2 R denotes hydrogen or methyl group, or a pharmaceutically acceptable salt thereof.

Abstract: A method of restoring the immune response of a patient having a lowered immune response level is provided, in which the patient is given an effective amount of certain nitrogen-containing polysaccharides derived from Coriolus versicolor (Fr.) Quel, where the polymer units having a molecular weight of below about 5,000 have been removed therefrom.

Abstract: Disclosed herein are a derivative of a substituted cephalosporanic acid, represented by the formula (I): ##STR1## wherein p is 0, 1 or 2 and R.sup.1 represents a hydrogen atom, a hydroxyl group, a carbamoyl group, an alkyl group having 1 to 4 carbon atoms or --(CONH).sub.m (CH.sub.2).sub.n --COOH wherein m is 0 or 1; n is 0, 1 or 2 and the carboxyl group may have been converted to the salt or the ester thereof, and an antibiotic comprising a derivative of substituted cephalosporanic acid represented by the formula (I).

Abstract: Disclosed herein are 7-beta-[2-(2-amino-4-thiazolyl)-2-methoxyiminoacetamido]-3-(2-amino-1,3,4- thiadiazolyl-5-thiomethyl)-3-cepheme-4-carboxylic acid, salts thereof and pivaloyloxymethyl ester thereof, and a pharmaceutical composition containing the same as an active ingredient.

Abstract: Disclosed is a pharmaceutical composition containing an aminobenzoic acid derivative as an active ingredient represented by the following general formula: ##STR1## wherein .sup.1 R donotes one member selected from the group consisting of the residual groups formed by removing OH at 1(alpha) or 1(beta) position from arabinose, glucose, galactose and mannose, or a pharmaceutically acceptable salt thereof.

Abstract: Disclosed is a method for the treatment of hyperglycemia, hyperlipemia, inflammatory diseases, pains due to the accentuation of central nerve, pyrexia due to the accentuation of central nerve or tumor, which comprises administering to a patient suffering therefrom a pharmaceutically effective amount of p-aminobenzoic acid-N-L-rhamnoside or a pharmaceutically acceptable salt thereof.

Abstract: Disclosed herein is a nucleic acid-containing glycoprotein having molecular weight of 5,000 to 300,000 as determined by ultracentrifugal method; the weight ratio of protein moiety thereof determined by Lowry-Folin's method to saccharide moiety thereof determined by phenol-sulfuric acid method of in the range of 50/50 to 80/20; N-terminal amino acid thereof consisting essentially of tyrosine, leucine or alanine; leucine-phenylalanine-valine as amino acid sequence at C-terminal thereof; the elementary composition consisting essentially of 35.2 to 49.3% of C, 4.8 to 8.0% of H, 4.3 to 12.3% of N, trace to 2.5% of S, trace to 1.2% of P and the balance of O; the isoelectric point of in the range of pH 2.5 to 5.0; and nucleic acid as a component.

Abstract: Disclosed is a pharmaceutical composition containing p-aminobenzoic acid-N-L-rhamonoside or a pharmaceutically acceptable salt thereof as an active ingredient.

Abstract: Disclosed is a method for the treatment of hyperglycemia, hyperlipemia, inflammatory diseases, pains due to the accentuation of central nerve, pyrexia due to the accentuation of central nerve or tumor, which comprises administering to a patient suffering therefrom a pharmaceutically effective amount of p-aminobenzoic acid-N-L-rhamnoside or a pharmaceutically acceptable salt thereof.

Abstract: Disclosed is a pharmaceutical composition containing an aminobenzoic acid derivative as an active ingredient represented by the following general formula: ##STR1## wherein .sup.1 R denotes one member selected from the group consisting of the residual groups formed by removing OH at 1(alpha) or 1(beta) position from arabinose, glucose, galactose and mannose, or a pharmaceutically acceptable salt thereof.

Abstract: Disclosed herein is a pharmaceutical composition in dosage unit form, which comprises a dosage effective for treating nephritic disease of a compound of 24,25-dihydroxycholecalciferol as an active ingredient and a pharmaceutically acceptable carrier.

Abstract: Polysaccharides having antitumor and other useful pharmacological activities and a process for preparing such polysaccharides are disclosed. These polysaccharides are characterized by .alpha.-bonding of the saccharide component and can be produced from the extracts obtained by the extraction of a basidiomycetous fungus belonging to the genus Coriolus or cultures thereof with an aqueous solvent.

Abstract: Disclosed is a method for the treatment of hyperglycemia, hyperlipemia, inflammatory diseases, pains due to the accentuation of central nerve, pyrexia due to the accentuation of central nerve or tumor, which comprises administering to a patient suffering therefrom a pharmaceutically effective amount of p-aminobenzoic acid-N-L-rhamnoside or a pharmaceutically acceptable salt thereof.

Abstract: Disclosed herein is a pharmaceutical composition in dosage unit form, which comprises a dosage effective for treating osteoporosis of a compound of 24,25-dihydroxycholecalciferol and a pharmaceutically acceptable carrier.